# Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)

> **NCT06234345** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 1252 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg
- **DRUG:** Comparator - Trimbow®

## Key facts

- **NCT ID:** NCT06234345
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 1252 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06234345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06234345, "Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06234345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*